SAN FRANCISCO, Jan. 14, 2026 /PRNewswire/ -- The Cloud Native Computing Foundation® (CNCF®), which builds sustainable ecosystems for cloud native software, today announced the graduation of Dragonfly, ...

Inside IBM’s main research center rises a maze of silver towers, each 22 feet tall. Through their vented flanks, you catch glimpses of blinking lights and the shadows of wires. The machine’s ...

Laurel (Miss.) West Jones four-star offensive lineman Bryson Cooley has officially flipped his commitment from the LSU Tigers to the Alabama Crimson Tide on the final day of the Early Signing Period.

Bossier City (La.) Airline four-star wide receiver Kenny Darby has committed to Will Stein and the Kentucky Wildcats where he's set to sign with the SEC program, he announced on Friday. Darby, the No.

Alphabet (GOOG) unveiled its Willow quantum processor a while back. CEO Sundar Pichai compared quantum computing’s current phase to where AI was five years ago. IonQ trades at a $17B valuation but ...

HUNTSVILLE — Jerious Singletary and Tr’e Williams have each committed to their new schools on the first day of the early signing period. Singletary committed to North Texas, and Williams committed to ...

The biggest stories of the day delivered to your inbox.

Buffett has managed to consistently beat the market without investing heavily in the technology sector. Two leading artificial intelligence (AI) stocks Berkshire does own, however, are Alphabet and ...

AI developers sell services on a usage-based pricing model, but they are often locked into rigid, long-term contracts for underlying computing resources. Many investors are worried this is a flawed ...

Turkish, Qatari and Egyptian officials met Wednesday in Cairo to discuss the second phase of the Israel-Hamas ceasefire deal. The meeting is said to have included Turkey and Egypt's intelligence ...

Fans will be able to apply for single-match tickets based on exact match-ups and teams for group-stage games. High demand continues as the Early Ticket Draw sees inventory snatched up by fans in more ...

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to ...